QPPV.COM KNOWLEDGE ASSESSMENT

Fidanacogene Elaparvovec: AAV Gene Therapy for Haemophilia B and Pharmacovigilance

Test your understanding of the concepts covered by Fidanacogene Elaparvovec: AAV Gene Therapy for Haemophilia B and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is it useful to connect liver-test trajectories with factor IX trajectories in aggregate analysis?
Question 2 of 10 Which statement best distinguishes acute infusion reactions from the principal long-term pharmacovigilance challenge?
Question 3 of 10 When reviewing a thrombotic event after treatment, which set of factors is most appropriate to assess?
Question 4 of 10 Which approach best assesses a bleed occurring after gene therapy?
Question 5 of 10 Which case description provides the strongest pharmacovigilance assessment of a report of elevated liver enzymes?
Question 6 of 10 Why must pharmacovigilance for fidanacogene elaparvovec extend well beyond the administration date?
Question 7 of 10 A patient develops aminotransferase elevations after treatment. Which additional information is most important for understanding the potential relationship between hepatic toxicity and efficacy?
Question 8 of 10 What is the principal therapeutic rationale for delivering the F9 transgene to hepatocytes?
Question 9 of 10 Before a patient who received gene therapy undergoes surgery, which information is most important for haemostasis planning and follow-up?
Question 10 of 10 Which record structure best preserves long-term traceability for a one-time gene therapy?

Select an answer to continue.

QPPV.com